Two new studies have reached profoundly different conclusions on the relationship between e-cig usage by young people and their take-up up of conventional tobacco – differences that may be partially explained by one coming from the U.S. and one from the UK.
The U.S. Food and Drug Administration (FDA) is facing another legal challenge to its new deeming regulation on e-cigarettes. Filed in the Southern District of West Virginia on 10th June, the action was taken by Larry W. Faircloth, a Republican member of West Virginia’s House of Delegates who is described as a user of e-cigarette devices and liquid nicotine.
The majority of American vapers were unaware of the new deeming regulations for e-cigarettes from the U.S. Food and Drug Administration (FDA) until they were published last month – and many may remain so, a new survey seems to imply.
Membership in a trade association is no guarantee that online e-cigarette sellers will adopt measures such as warning labels and age verification, according to a new U.S. study, despite industry bodies often arguing that their members lead the way.
Two new studies on the correlation between youth vaping and e-cigarette advertising are likely to be used to support calls for regulation of marketing – but they may add less to the debate than they seem, being based on the same previously-published numbers.
Plaintiffs’ attorneys in the U.S. are always on the hunt for a new target to sue. And, having had some success suing diacetyl manufacturers over workers’ exposure to the chemical in microwave popcorn plants, attorneys are now beginning to target coffee roasters and the e-cigarette industry as well.
E-liquid maker Lost Art Liquids has filed suit against the U.S. Food and Drug Administration (FDA), claiming that the deeming regulations violate two parts of the U.S. Constitution and two important statutes.
A new systematic review of e-cigarettes and smoking cessation is claimed to be the most comprehensive so far as it covers not only published, peer-reviewed studies – including observational research as well as RCTs – but also so-called “grey literature”, material published outside of peer review.
Some of America’s most trusted public-health institutions have been accused of failing to tell consumes about the relative risk of smokeless nicotine products compared with cigarettes, a policy that is likely to cost lives.
Some larger independent e-cigarette companies support the new rules from the U.S. Food and Drug Administration (FDA), despite the debate over them being widely portrayed as an argument between Big Tobacco and health organisations on one side versus indie e-cig firms on the other.
U.S. media reactions to the new deeming rule ran the gamut from praise for an FDA which had produced “sensible regulations”, to damning criticism for an agency which will supposedly do more to promote smoking than to stop it.
The U.S. Food and Drug Administration (FDA) believes most e-cigarette manufacturers will need to conduct fresh scientific research in order to obtain authorisation for their products under the newly-published deeming regulations – but not necessarily full-blown clinical studies.
Differences between the FDA’s final deeming regulations and its 2014 draft version reveal many changes in areas ranging from retailing and health warnings to compliance timetables and product definitions.
The new deeming regulations from the U.S. Food and Drug Administration (FDA) will limit the regulatory authority of states and localities in a wide range of areas, with e-cigarette labelling proving to be one of the most contentious.
The era of vape stores producing their own e-liquids is likely to come to an end after the introduction of the deeming regulations in the U.S., the agency responsible for them predicts. The Food and Drug Administration (FDA) says it “expects that most vape shops will stop mixing e-liquids“ because if they continue to do so they will fall under » Continue Reading.
Several members of Congress welcomed what they view as a long-overdue rule by the U.S. Food and Drug Administration (FDA) to regulate e-cigarettes, but the initial responses also provided another opportunity for Democrats and Republicans to show how divided they are when it comes to adding new federal oversight.
Initial industry reaction broke down largely along expected lines – with many of the usual faces popping in with early assessments. Further reaction is expected as more people get to grips with the massive U.S. Food and Drug Administration (FDA) regulatory document.
Striving for science-based policy-making in the deeming regulations, the FDA faced a tough task in attempting to corral the rapidly-developing and often contradictory data on e-cigarettes at the same time as it was dealing with pleas and criticisms from the industry and pressure groups.